Daré Bioscience, Inc. (DARE)
NASDAQ: DARE · Real-Time Price · USD
0.6438
-0.0021 (-0.33%)
Oct 26, 2026, 4:00 PM EDT - Market closed
Daré Bioscience Revenue
Daré Bioscience had revenue of $187.55K in the quarter ending June 30, 2026. This brings the company's total for the last twelve months to $1.37M. In the year 2025, Daré Bioscience had annual revenue of $1.03M with 10,429.36% growth. That makes Daré Bioscience the 43,123rd largest company in the world by revenue and 5,956th in the United States.
Revenue (ttm)
$1.37M
Revenue Growth
+10,429.36%
P/S Ratio
9.27
Revenue / Employee
$56,914
Employees
24
Market Cap
12.66M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.03M | 1.02M | 10,429.36% |
| Dec 31, 2024 | 9.78K | -2.80M | -99.65% |
| Dec 31, 2023 | 2.81M | -7.19M | -71.92% |
| Dec 31, 2022 | 10.00M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | 80.00K | 74.00K | 1,233.33% |
| Dec 31, 2013 | 6.00K | -619.00K | -99.04% |
| Dec 31, 2012 | 625.00K | 619.00K | 10,316.67% |
| Dec 31, 2011 | 6.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| TScan Therapeutics | 7.11M |
| Bolt Biotherapeutics | 4.70M |
| SeaStar Medical Holding | 1.71M |
| Vyome Holdings | 129.73K |
| BioCardia | 3.00K |
DARE News
- 21 hours ago - Daré Bioscience to Showcase Its Investigational Programmable Device, DARE-IDDS, at PODD 2026: One Device, Designed to Deliver 100+ Doses and to be Controlled Wirelessly - GlobeNewsWire
- 23 hours ago - Dare Bioscience initiated with a Buy at Ladenburg - TheFly
- 7 days ago - Daré Bioscience Sponsors HERmedicine Educational Program for Clinicians on Managing Menopause After Breast Cancer - GlobeNewsWire
- 13 days ago - Daré Bioscience Launches “CEO Corner” Video Series to Highlight the Company's Pipeline of Women's Health Innovations, Corporate Strategy and Opportunities - GlobeNewsWire
- 18 days ago - Dare Bioscience to present Sildenafil Cream data at SMSNA meeting - TheFly
- 20 days ago - Daré Bioscience Proxy statement: Proxy filing - Filings
- 4 weeks ago - Dare Bioscience announces issuance of patent for DARE-HPV program - TheFly
- 4 weeks ago - Dare Bioscience Announces New U.S. Patent Strengthening DARE-HPV Program as a Potential First FDA-Approved Pharmacologic Treatment for HPV Infection - GlobeNewsWire